Literature DB >> 6835353

Immunostimulation with muramyl dipeptide and its desmethyl analogue: Studies of non-specific resistance to pulmonary blastomycosis in inbred mouse strains.

P A Morozumi, E Brummer, D A Stevens.   

Abstract

N-acetyl-muramyl-L-alanyl-D-isoglutamine (MDP) protected against pulmonary blastomycosis when given prophylactically to BALB/c mice. Its desmethyl analogue (DM-MDP) had a similar effect. In C3H/HeJ, the effect was less marked. Early treatment after infection, with MDP and DM-MDP, had a modest effect in C3H/HeJ and BALB/c respectively, whereas late treatment had no effect in any mouse strain. No effect could be demonstrated with challenge sizes producing too lethal a model or minimal lethality, or in DBA/2J or young BALB/c mice. The effects in various strains do not correlate with differing effects on nonspecific immunostimulation in these strains. Immunostimulation with glycopeptides deserves further study in prophylaxis or therapy of fungal infection.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6835353     DOI: 10.1007/bf00443907

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  11 in total

1.  Direct augmentation of cytolytic activity of tumor-derived macrophages and macrophage cell lines by muramyl dipeptide.

Authors:  T Taniyama; H T Holden
Journal:  Cell Immunol       Date:  1979-12       Impact factor: 4.868

2.  Opposite modulation of lymph node cell and spleen cell responses to mitogens by muramyl dipeptide and its desmethyl analog.

Authors:  E Brummer; D A Stevens
Journal:  Cell Immunol       Date:  1981-03-15       Impact factor: 4.868

3.  In vitro responsiveness of immunocytes to a synthetic immunoadjuvant, muramyl dipeptide, and different synthetic analogs.

Authors:  C Damais; M Parant; L Chedid
Journal:  Antibiot Chemother (1971)       Date:  1978

4.  Defective tumoricidal capacity of macrophages from C3H/HeJ mice.

Authors:  L P Ruco; M S Meltzer
Journal:  J Immunol       Date:  1978-01       Impact factor: 5.422

5.  Mouse model of pulmonary blastomycosis: utility, simplicity, and quantitative parameters.

Authors:  R P Harvey; E S Schmid; C C Carrington; D A Stevens
Journal:  Am Rev Respir Dis       Date:  1978-04

6.  The pyrogenicity of the synthetic adjuvant muramyl dipeptide and two structural analogues.

Authors:  C A Dinarello; R J Elin; L Chedid; S M Wolff
Journal:  J Infect Dis       Date:  1978-12       Impact factor: 5.226

7.  Maturity as a critical determinant of resistance to fungal infections: studies in murine blastomycosis.

Authors:  C Brass; D A Stevens
Journal:  Infect Immun       Date:  1982-04       Impact factor: 3.441

8.  Susceptibility differences of inbred strains of mice to blastomycosis.

Authors:  P A Morozumi; J W Halpern; D A Stevens
Journal:  Infect Immun       Date:  1981-04       Impact factor: 3.441

9.  In vitro spleen cell responsiveness to various analogs of MDP (N-acetylmuramyl-L-alanyl-D-isoglutamine), a synthetic immunoadjuvant, in MDP high-responder mice.

Authors:  C Damais; M Parant; L Chedid; P Lefrancier; J Choay
Journal:  Cell Immunol       Date:  1978-01       Impact factor: 4.868

10.  Strain differences in resistance to infection reversed by route of challenge: studies in blastomycosis.

Authors:  P A Morozumi; E Brummer; D A Stevens
Journal:  Infect Immun       Date:  1981-11       Impact factor: 3.441

View more
  4 in total

1.  Anti-infectious activity of liposomal muramyl dipeptides in immunodeficient CBA/N mice.

Authors:  N C Phillips; L Chedid
Journal:  Infect Immun       Date:  1987-06       Impact factor: 3.441

2.  Problems in antifungal chemotherapy.

Authors:  D A Stevens
Journal:  Infection       Date:  1987 Mar-Apr       Impact factor: 3.553

3.  Uveitis induction in the rabbit by muramyl dipeptides.

Authors:  R V Waters; T G Terrell; G H Jones
Journal:  Infect Immun       Date:  1986-03       Impact factor: 3.441

4.  Synergistic effect of glucantime and a liposome-encapsulated muramyl dipeptide analog in therapy of experimental visceral leishmaniasis.

Authors:  L E Adinolfi; P F Bonventre; M Vander Pas; D A Eppstein
Journal:  Infect Immun       Date:  1985-05       Impact factor: 3.441

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.